Coverage ended 5 updates · Last at 7:45am ET

Live: Tilray Brands (TLRY) Q1 FY2026 Earnings Coverage

By Joel South · Updated Oct 9, 7:45am ET · Published Oct 9, 6:15am ET

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Live Updates

Newest first

Guidance Update

Tilray reiterated its FY2026 Adjusted EBITDA outlook of $62M–$72M, signaling confidence in execution despite mixed segment margins.

The company noted continued focus on operational discipline and expects margin recovery as Project 420 optimization and beverage integration synergies take hold.

Guidance Metric FY2026 Range Prior Outlook Direction
Adj. EBITDA $62M–$72M $62M–$72M ⚖️ Flat
Cannabis Market Share Maintain #1 Canada Maintain ⚖️ Flat
Cash Flow Continued improvement Prior trend intact 📈 Improved

Management Commentary

CEO Irwin Simon said the quarter “underscores the effectiveness of our strategic vision and disciplined execution,” highlighting record revenue, profitability, and balance sheet strength as “proof points of sustainable growth.”

He added that Tilray’s global platform is positioned to lead the evolution of the global cannabis, beverage, and wellness sectors and that U.S. rescheduling and European legalization remain pivotal tailwinds.

Quick Take: The tone was notably confident — emphasizing global positioning and fiscal discipline rather than cost-cutting. Tone Meter: Improving

Key Operating Highlights

Segment Revenue YoY Change Gross Margin QoQ Trend Commentary
Cannabis $64.5M +5% 36% (–4pts) Stable Maintained #1 Canadian market share; International +10% YoY.
Beverage $55.7M Flat 38% (–3pts) Stabilizing Margin compression from integration, but SKU optimization largely complete.
Wellness $15.2M +3% 32% Flat Solid performance from Manitoba Harvest and hemp foods.
Distribution $74.0M +9% 11% (–1pt) Strong Growth in CC Pharma and European supply chain volumes.
Adj. EBITDA $10.2M +9% — ↑ Driven by cost savings and integration synergies.

What Changed This Quarter

  • ✅ First quarterly net income in over a year — a psychological and financial milestone.

  • ✅ Operational cash use nearly eliminated, improving $34M YoY.

  • ⚖️ Gross margin dipped to 27% (vs. 30% prior) as beverage and cannabis mix remained margin-heavy.

  • 📈 Debt reduced to $4M net, leverage ratio at just 0.07x EBITDA — a major balance sheet win.

  • 📉 Beverage segment still soft, with 38% margin vs. 41% YoY.

  • ⚖️ Guidance held steady, suggesting confidence without overpromising.

Tilray is demonstrating tangible progress in cash discipline and profitability while keeping its strategic bets on U.S. and EMEA cannabis optionality alive. The print confirms the company’s path toward sustainable EBITDA and free cash flow, making it a credible multi-vertical turnaround story rather than a pure cannabis speculation play.

Tilray Up Big After Earnings

Tilray shares are up 14% after posted record Q1 FY2026 revenue of $209.5 million, up 5% YoY and above consensus of $205.75M 
Adjusted EPS came in at $0.00, in line with expectations, while net income reached $1.5 million, marking a turnaround from a $(34.7)M loss a year ago.

Adjusted EBITDA rose 9% YoY to $10.2 million, also exceeding forecasts, with cash used in operations improving by $34 million.

Metric Actual Estimate YoY Change Beat/Miss
Revenue $209.5M $205.75M +5% ✅ Beat
EPS (Adj.) $0.00 $0.00 +$0.01 ⚖️ In Line
Net Income $1.5M – vs. $(34.7)M ✅ Turnaround
Adj. EBITDA $10.2M ~$9.3M +9% ✅ Beat
Cash Flow (Ops.) $(1.3)M – +$34M YoY ✅ Improved

 

Live coverage has ended. The full story is below.

Full Coverage

The story so far

Tilray Brands (NASDAQ: TLRY) reports fiscal Q1 2026 results before the market opens, following a transition year defined by consolidation and margin repair. The stock is up 275% over the past 6 months as investors look to see if the turnaround can keep momentum moving forward. 

Last quarter’s print (Q4 FY2025) showed clear progress — EPS beat $0.02 vs. est. $0.00 — as international cannabis and spirits drove gross margin expansion. Yet shares finished down 5% after weaker beverage margins and cautious cash-flow trends.

This quarter’s release will test whether Tilray’s profitability narrative is sustainable amid muted cannabis volume and continued beverage rationalization.

Estimates Snapshot

Metric Q1 FY2026 Estimate YoY Change FY2026 Estimate FY2027 Estimate
Revenue $205.75 M +2.9 % vs $200 M $863.47 M $901.79 M
EPS (Normalized) $0.00 +$0.01 vs –$0.01 prior year $0.04 –$0.07
Analyst Range (FY26) $830.5 M – $891.5 M rev / $0.03 – $0.04 EPS

Tilray has beaten EPS estimates four consecutive quarters, but top-line momentum remains constrained as the company trims low-margin SKUs and channels.

Consensus implies low-single-digit growth early in FY26, improving into the back half as Project 420 synergies ($33 M target) and AI-driven greenhouse automation start to flow through.

Key Areas To Watch

  • International Medical Cannabis Expansion – Germany and Poland were standouts in Q4, with +134% YoY German growth and new self-pay market entry. Investors expect continued EMEA gains under Managing Director Rajnish Ohri, who leads Tilray’s push into the Middle East & Asia.

  • Beverage & Project 420 Margins – Integration of SweetWater, Montauk, and Shock Top has depressed beverage margin (38% vs 53% YoY). The focus this quarter: sequential recovery as SKU optimization winds down and holiday distribution begins.

  • THC & Wellness Flywheel – Hemp-derived THC beverages now reach 1,300 U.S. retail points across 13 states, while HiBall Energy and Manitoba Harvest sustain mid-single-digit growth. Watch for early regulatory commentary on interstate THC distribution.

  • Canadian Cannabis Share Dynamics – After reclaiming the #1 flower slot in Q4 via Redecan & Broken Coast, any volume recovery would signal a turning point in Tilray’s domestic optimization strategy.

  • Cash & Leverage Profile – Last quarter’s free cash flow (–$121 M) and cash balance $256 M left Tilray’s net-debt-to-EBITDA at 0.3× — a manageable base but still sensitive to integration costs. Sustained EBITDA above $25 M would confirm a credible path toward the FY26 goal of $62–72 M.

Contact [email protected] for any questions or corrections.

Disclaimer: Investing in securities involves a risk of loss. Past performance is never a guarantee of future returns. Investing in foreign stock markets involves additional risks, such as the risk of currency fluctuations. Guides are provided by Fisher Investments. The publisher may be compensated when readers request a guide.
Joel South

Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.

He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.

All articles →